Travere Therapeutics, Inc. (TVTX) shares jumped 31.57 percent to $40.42, gaining $9.72 on Monday, after the company received U.S. Food and Drug Administration approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis.
The stock is currently trading at $40.42, up from its previous close of $30.70 on the Nasdaq. It opened at $41.53 and has traded in a range of $39.90 to $42.50 during the session, with volume reaching 6.94 million shares compared to an average of 1.52 million shares.
The approval marks FILSPARI as the first and only FDA-approved treatment for FSGS, expanding its use beyond IgA nephropathy. Clinical data showed significant reductions in proteinuria, supporting its potential as a key therapy for this rare kidney disease. The 52-week range for the stock is $13.88 to $42.50.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.